Cnpair Biotech

Executive Summary

Cnpair Biotech is a Shanghai-based private biotechnology company specializing in the discovery and development of therapeutic antibodies for oncology and immunology. Founded in 2015, the company leverages advanced antibody engineering to address high unmet medical needs in complex diseases. Currently in Phase 1 clinical stage with a workforce of 50-200 employees, Cnpair aims to advance its pipeline of novel biologic drugs. While specific financial and pipeline details are not publicly disclosed, the company operates in the rapidly growing Chinese biotech sector, focusing on targets with significant market potential. The company's progress will depend on successful clinical validation and potential partnership opportunities.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Data Readout for Lead Asset15% success
• Q2 2027IND Filing for Next-Generation Antibody Candidate25% success
• 2027Strategic Partnership or Licensing Deal30% success